Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R.

PropertyValue
dbo:abstract
  • Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R. Squibb and Sons in the 1970s.
dbo:atcPrefix
  • none
dbo:casNumber
  • 34966-41-1
dbo:fdaUniiCode
  • 8K93Z46WPY
dbo:iupacName
  • ethyl 4-(butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
dbo:pubchem
  • 37015
dbo:thumbnail
dbo:wikiPageID
  • 28642033 (xsd:integer)
dbo:wikiPageRevisionID
  • 633365727 (xsd:integer)
dbp:atcPrefix
  • none
dbp:c
  • 15 (xsd:integer)
dbp:casNumber
  • 34966 (xsd:integer)
dbp:chembl
  • 8184 (xsd:integer)
dbp:chemspiderid
  • 33966 (xsd:integer)
dbp:h
  • 22 (xsd:integer)
dbp:hasPhotoCollection
dbp:iupacName
  • ethyl 4--1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
dbp:legalStatus
  • Uncontrolled
dbp:molecularWeight
  • 290.360000 (xsd:double)
dbp:n
  • 4 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 37015 (xsd:integer)
dbp:routesOfAdministration
dbp:smiles
  • O=COCC
dbp:unii
  • 8 (xsd:integer)
dct:subject
rdf:type
rdfs:comment
  • Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R.
rdfs:label
  • Cartazolate
owl:sameAs
http://www.w3.org/ns/prov#wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is foaf:primaryTopic of